Iterum Therapeutics
ITRM
ITRM was delisted on the 31st of March, 2026.
50 hedge funds and large institutions have $11.2M invested in Iterum Therapeutics in 2021 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 4 closing their positions.
775% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 4
500% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 1
163% more funds holding
Funds holding: 19 → 50 (+31)
62% more capital invested
Capital invested by funds: $6.91M → $11.2M (+$4.29M)
0.65% less ownership
Funds ownership: 0.95% → 0.3% (-0.65%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$683K |
| 2 |
HF
HRT Financial
New York
|
+$618K |
| 3 |
IA
Insight Advisors
Newtown,
Pennsylvania
|
+$482K |
| 4 |
FNBT
FineMark National Bank & Trust
Fort Myers,
Florida
|
+$476K |
| 5 |
Two Sigma Advisers
New York
|
+$316K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBPIA
Pivotal bioVenture Partners Investment Advisor
San Francisco,
California
|
-$935K |
| 2 |
Renaissance Technologies
New York
|
-$725K |
| 3 |
SSG
Summit Securities Group
New York
|
-$54K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$37K |
| 5 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
-$15K |
ITRM Hedge Fund Activity: Q1 2021 in Review
50 institutional investors reported a position in Iterum Therapeutics (ITRM) for Q1 2021, worth a combined $11.2M — up 62% from $6.91M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new ITRM positions and 4 closed out — a net gain of 31 holders — while 6 added to existing stakes and 1 trimmed.
The largest buyer was Two Sigma Investments, opening a new position worth an estimated $683K. The largest seller was Pivotal bioVenture Partners Investment Advisor, exiting entirely with an estimated $935K sold.
- 50 institutional investors held Iterum Therapeutics (ITRM) as of Q1 2021, up from 19 in Q4 2020.
- Funds reported $11.2M of Iterum Therapeutics stock for Q1 2021, up 62% quarter-over-quarter.
- 35 funds opened new Iterum Therapeutics positions in Q1 2021 and 4 closed out, a net change of +31 holders.
- The largest Iterum Therapeutics buyer in Q1 2021 was Two Sigma Investments, an estimated $683K added.
- The largest Iterum Therapeutics seller in Q1 2021 was Pivotal bioVenture Partners Investment Advisor, an estimated $935K sold.
Based on aggregated 13F filings for Q1 2021.